Cannabidiol is currently a class B1 controlled drug in New Zealand under the Misuse of Drugs Act. It is also a prescription medicine under the Medicines Act. In 2017 the rules were changed so that anyone wanting to use it could go to the Health Ministry for approval. Prior to this, the only way to obtain a prescription was to seek the personal approval of the Minister of Health.
In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
Prolonged use at high doses has not shown potential for abuse of CBD. In fact, a clinical study published in 2018 found that recreational polydrug users did not show abuse potential with use of CBD. Long-term studies have not evaluated potential changes in hormonal balance or long-term adverse changes in liver function, though prolonged use of CBD enhances metabolism of certain drugs. Stopping CBD oil suddenly has not been associated with withdrawal effects.